Dr. Levine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5090 N 40th St
Ste 250
Phoenix, AZ 85018Phone+1 602-258-3354
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 1994 - 1997- Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1993 - 1994
Duke University School of MedicineClass of 1993
Certifications & Licensure
AZ State Medical License 1998 - 2027
WV State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
UT State Medical License 2023 - 2026
IA State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
IL State Medical License 2023 - 2026- American Board of Psychiatry and Neurology Neurology
- Join now to see all
Awards, Honors, & Recognition
- Top Doctors:Arizona State Castle Connolly, 2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2008 Jun 01
- Safety Study of High Doses of Zinc in ALS Patients Start of enrollment: 2010 Oct 01
- Dermatomyositis and Polymyositis Registry Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 54 citationsPhase I clinical trial of safety of L-serine for ALS patientsTodd Levine, Robert G. Miller, Walter G. Bradley, Dan H. Moore, David Saperstein
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2017-01-02 - 301 citationsRituximab in the treatment of dermatomyositis: an open-label pilot study.Todd D. Levine
Arthritis and Rheumatism. 2005-02-01 - 192 citationsIgM antibody-related polyneuropathies: B-cell depletion chemotherapy using RituximabTodd Levine, Alan Pestronk
Neurology. 1999-05-01
Press Mentions
Phase 2 Trial Testing H.P. Acthar Gel for ALS Enrolls Half of Patients, Still RecruitingJune 25th, 2019- Clinical Trial Tests H.P. Acthar Gel as Potential ALS TreatmentJune 20th, 2017
![FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)](https://doximity-res.cloudinary.com/image/upload/v1/ingestion_media/zqx0on8czadbz5btyblj.png)
FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)May 23rd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
